StreetInsider.com News Articles

RedChip Showcases Public Companies Across the Artificial Intelligence Value Chain at March 19 Virtual Investor Conference

Mon, 09 Mar 2026 07:30:00 -0400

ORLANDO, FL / ACCESS Newswire / March 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming AI Investor Conference: From Data Centers to Breakthrough Use Cases, taking place March 19, 2026, from 9:30 a.m. to 4:00 p.m. ET. The full-day virtual event will spotlight publicly traded companies developing, enabling, and deploying artificial intelligence technologies across infrastructure, analytics, automation, and applied industry solutions, offering investors direct access to management teams driving innovation across the AI value chain.

Registration is free

RedChip Showcases Public Companies Across the Artificial Intelligence Value Chain at March 19 Virtual Investor Conference

Mon, 09 Mar 2026 07:30:00 -0400

ORLANDO, FL / ACCESS Newswire / March 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming AI Investor Conference: From Data Centers to Breakthrough Use Cases, taking place March 19, 2026, from 9:30 a.m. to 4:00 p.m. ET. The full-day virtual event will spotlight publicly traded companies developing, enabling, and deploying artificial intelligence technologies across infrastructure, analytics, automation, and applied industry solutions, offering investors direct access to management teams driving innovation across the AI value chain.
Registration is free

RedChip Showcases Public Companies Across the Artificial Intelligence Value Chain at March 19 Virtual Investor Conference

Mon, 09 Mar 2026 07:30:00 -0400

ORLANDO, FL / ACCESS Newswire / March 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming AI Investor Conference: From Data Centers to Breakthrough Use Cases, taking place March 19, 2026, from 9:30 a.m. to 4:00 p.m. ET. The full-day virtual event will spotlight publicly traded companies developing, enabling, and deploying artificial intelligence technologies across infrastructure, analytics, automation, and applied industry solutions, offering investors direct access to management teams driving innovation across the AI value chain.
Registration is free

RedChip Showcases Public Companies Across the Artificial Intelligence Value Chain at March 19 Virtual Investor Conference

Mon, 09 Mar 2026 07:30:00 -0400

ORLANDO, FL / ACCESS Newswire / March 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming AI Investor Conference: From Data Centers to Breakthrough Use Cases, taking place March 19, 2026, from 9:30 a.m. to 4:00 p.m. ET. The full-day virtual event will spotlight publicly traded companies developing, enabling, and deploying artificial intelligence technologies across infrastructure, analytics, automation, and applied industry solutions, offering investors direct access to management teams driving innovation across the AI value chain.
Registration is free

RedChip Showcases Public Companies Across the Artificial Intelligence Value Chain at March 19 Virtual Investor Conference

Mon, 09 Mar 2026 07:30:00 -0400

ORLANDO, FL / ACCESS Newswire / March 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming AI Investor Conference: From Data Centers to Breakthrough Use Cases, taking place March 19, 2026, from 9:30 a.m. to 4:00 p.m. ET. The full-day virtual event will spotlight publicly traded companies developing, enabling, and deploying artificial intelligence technologies across infrastructure, analytics, automation, and applied industry solutions, offering investors direct access to management teams driving innovation across the AI value chain.
Registration is free

RedChip Showcases Public Companies Across the Artificial Intelligence Value Chain at March 19 Virtual Investor Conference

Mon, 09 Mar 2026 07:30:00 -0400

ORLANDO, FL / ACCESS Newswire / March 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming AI Investor Conference: From Data Centers to Breakthrough Use Cases, taking place March 19, 2026, from 9:30 a.m. to 4:00 p.m. ET. The full-day virtual event will spotlight publicly traded companies developing, enabling, and deploying artificial intelligence technologies across infrastructure, analytics, automation, and applied industry solutions, offering investors direct access to management teams driving innovation across the AI value chain.
Registration is free

RedChip Showcases Public Companies Across the Artificial Intelligence Value Chain at March 19 Virtual Investor Conference

Mon, 09 Mar 2026 07:30:00 -0400

ORLANDO, FL / ACCESS Newswire / March 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming AI Investor Conference: From Data Centers to Breakthrough Use Cases, taking place March 19, 2026, from 9:30 a.m. to 4:00 p.m. ET. The full-day virtual event will spotlight publicly traded companies developing, enabling, and deploying artificial intelligence technologies across infrastructure, analytics, automation, and applied industry solutions, offering investors direct access to management teams driving innovation across the AI value chain.
Registration is free

RedChip Showcases Public Companies Across the Artificial Intelligence Value Chain at March 19 Virtual Investor Conference

Mon, 09 Mar 2026 07:30:00 -0400

ORLANDO, FL / ACCESS Newswire / March 9, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced its upcoming AI Investor Conference: From Data Centers to Breakthrough Use Cases, taking place March 19, 2026, from 9:30 a.m. to 4:00 p.m. ET. The full-day virtual event will spotlight publicly traded companies developing, enabling, and deploying artificial intelligence technologies across infrastructure, analytics, automation, and applied industry solutions, offering investors direct access to management teams driving innovation across the AI value chain.
Registration is free

BullFrog AI faces potential NASDAQ delisting after missing equity requirements

Mon, 23 Feb 2026 06:04:30 -0400

BullFrog AI Holdings Inc. (NASDAQ: BFRG) received notice from NASDAQ on February 19, 2026, that the company failed to meet the terms of an extension to comply with minimum stockholders' equity requirements, according to a company statement.
The company initially received a noncompliance notice on August 21, 2025, for failing to maintain the required $2.5 million in stockholders' equity under NASDAQ Listing Rule 5550(b)(1). NASDAQ granted an extension until February 17, 2026, after the company submitted a compliance plan on September 30, 2025.
BullFrog AI's securities are now subject to delisting unless the company requests a hearing before an independent NASDAQ Hearings

Form 8-K BullFrog AI Holdings, For: Feb 19

Mon, 23 Feb 2026 06:02:00 -0400
si-local-file:///var/storage/secattach/20260223/26038677.html

Form 8-K BullFrog AI Holdings, For: Feb 19

Mon, 23 Feb 2026 06:02:00 -0400
si-local-file:///var/storage/secattach/20260223/26038677.html

Form 8-K BullFrog AI Holdings, For: Feb 10

Tue, 17 Feb 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260217/26013848.html

Form 8-K BullFrog AI Holdings, For: Feb 10

Tue, 17 Feb 2026 16:32:00 -0400
si-local-file:///var/storage/secattach/20260217/26013848.html

BullFrog AI publishes white paper on data harmonization

Tue, 27 Jan 2026 07:32:31 -0400

BullFrog AI Holdings Inc. (NASDAQ: BFRG; BFRGW) published a white paper titled "Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences" on January 27. The paper discusses the company's bfPREP technology for processing biomedical data.
The white paper addresses challenges in applying artificial intelligence to pharmaceutical drug development. "The rush to apply AI in biopharma drug development has resulted in many AI initiatives that fail, not due to the algorithm, but due to the resulting analysis that reflect data processing idiosyncrasies rather than biology," said BullFrog AI Founder and CEO Vin Singh.
The company's bfPREP technology processes raw biomedical data

BullFrog AI publishes white paper on data harmonization

Tue, 27 Jan 2026 07:32:31 -0400

BullFrog AI Holdings Inc. (NASDAQ: BFRG; BFRGW) published a white paper titled "Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences" on January 27. The paper discusses the company's bfPREP technology for processing biomedical data.
The white paper addresses challenges in applying artificial intelligence to pharmaceutical drug development. "The rush to apply AI in biopharma drug development has resulted in many AI initiatives that fail, not due to the algorithm, but due to the resulting analysis that reflect data processing idiosyncrasies rather than biology," said BullFrog AI Founder and CEO Vin Singh.
The company's bfPREP technology processes raw biomedical data

BullFrog AI on Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences

Tue, 27 Jan 2026 07:30:00 -0400

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, publishes a white paper titled, “Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences,” with a discussion on how BullFrog AI’s bfPREPTM immediately recognizes reliable patterns to transform raw biomedical data into harmonized, clinically contextualized formats, providing reliable insights and trustworthy analytical assets to assist in drug development.

“The rush to apply AI in biopharma

BullFrog AI on Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences

Tue, 27 Jan 2026 07:30:00 -0400

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, publishes a white paper titled, “Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences,” with a discussion on how BullFrog AI’s bfPREPTM immediately recognizes reliable patterns to transform raw biomedical data into harmonized, clinically contextualized formats, providing reliable insights and trustworthy analytical assets to assist in drug development.

“The rush to apply AI in biopharma

BullFrog AI on Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences

Tue, 27 Jan 2026 07:30:00 -0400

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, publishes a white paper titled, “Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences,” with a discussion on how BullFrog AI’s bfPREPTM immediately recognizes reliable patterns to transform raw biomedical data into harmonized, clinically contextualized formats, providing reliable insights and trustworthy analytical assets to assist in drug development.

“The rush to apply AI in biopharma

BullFrog AI on Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences

Tue, 27 Jan 2026 07:30:00 -0400

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, publishes a white paper titled, “Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences,” with a discussion on how BullFrog AI’s bfPREPTM immediately recognizes reliable patterns to transform raw biomedical data into harmonized, clinically contextualized formats, providing reliable insights and trustworthy analytical assets to assist in drug development.

“The rush to apply AI in biopharma

BullFrog AI on Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences

Tue, 27 Jan 2026 07:30:00 -0400

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, publishes a white paper titled, “Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences,” with a discussion on how BullFrog AI’s bfPREPTM immediately recognizes reliable patterns to transform raw biomedical data into harmonized, clinically contextualized formats, providing reliable insights and trustworthy analytical assets to assist in drug development.

“The rush to apply AI in biopharma

BullFrog AI on Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences

Tue, 27 Jan 2026 07:30:00 -0400

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, publishes a white paper titled, “Data Harmonization: The Hidden Prerequisite for Reliable AI/ML in Life Sciences,” with a discussion on how BullFrog AI’s bfPREPTM immediately recognizes reliable patterns to transform raw biomedical data into harmonized, clinically contextualized formats, providing reliable insights and trustworthy analytical assets to assist in drug development.

“The rush to apply AI in biopharma

Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus

Tue, 06 Jan 2026 09:30:40 -0400

DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and data-driven precision platforms.

Alumis (NASDAQ: ALMS): Phase 3 Data Redefines the Oral Psoriasis Landscape

Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib, its next-generation oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis.

Both trials met all primary and secondary endpoints with high statistical significance, with efficacy that stands out among oral therapies. By Week

Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus

Tue, 06 Jan 2026 09:30:40 -0400

DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and data-driven precision platforms.

Alumis (NASDAQ: ALMS): Phase 3 Data Redefines the Oral Psoriasis Landscape

Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib, its next-generation oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis.

Both trials met all primary and secondary endpoints with high statistical significance, with efficacy that stands out among oral therapies. By Week

Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus

Tue, 06 Jan 2026 09:30:40 -0400

DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and data-driven precision platforms.

Alumis (NASDAQ: ALMS): Phase 3 Data Redefines the Oral Psoriasis Landscape

Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib, its next-generation oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis.

Both trials met all primary and secondary endpoints with high statistical significance, with efficacy that stands out among oral therapies. By Week

Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus

Tue, 06 Jan 2026 09:30:40 -0400

DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Markets are opening with a clear appetite for substance over speculation, as investors gravitate toward companies delivering late-stage clinical wins, scalable science, and data-driven precision platforms.

Alumis (NASDAQ: ALMS): Phase 3 Data Redefines the Oral Psoriasis Landscape

Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib, its next-generation oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis.

Both trials met all primary and secondary endpoints with high statistical significance, with efficacy that stands out among oral therapies. By Week